In June 2011, the FDA released new guidelines for sunscreen labels. These labels were to hit store shelves by June 2012, but have now been pushed back.
Last month the FDA announced that they were pushing back the FDA label implementation date until December 2012. Smaller companies with less than $25,000 in sales will have until June 2013 to update their labels. This means that your patients will have to spend another summer decoding confusing sunscreen labels.
U.S. Senators and other lawmakers expressed anger and frustration at the delay.
“The FDA took a major step backwards today and as a result, more consumers will likely get burned this summer,” said Sen. Jack Reed, D-R.I.
These updated labels are meant to reduce consumer confusion about what kind of sun protection to buy. Labels with the phrase “Broad Spectrum” must block both UVA and UVB rays. Terms like sunblock, waterproof, and sweatproof will no longer be allowed, nor will unrealistic SPF levels, like SPF 100. Sunscreens with an SPF lower than 15 will have a warning that states: “This product has been shown only to help prevent sunburn, not skin cancer or early skin aging.” New sunscreen labels must also show how often the sunscreen should be reapplied.
Sunscreen manufacturers and lobbyists for cosmetics and over-the-counter pharmaceutical industries said they needed more than one year to change the labels, and warned that there may be sunscreen shortages if the new labels were to go into effect next month.
[image by George Ruiz]
This video features highlights from the SDPA Annual Summer Dermatology Conference held June 1 – 5, 2016 in Austin, Texas. The Austin conference set an attendance record for a summer SDPA conference and included dynamic speakers and panel discussions as well as great networking events. Visit the sdpaconferences.org website for […]
June 24, 2016
Dr. Sharon Jacob presented a lecture at the SDPA Annual Summer Dermatology Conference last year (2014) in Orlando, FL, about the first pediatric patch testing registry. She highlighted some of the differences between registry studies and clinical studies and listed the benefits of participation.
June 1, 2016
Dermatology News recently published a letter by Brett Coldiron, MD seeking to clarify Medicare’s “incident to” billing when working with PAs in the office. We can agree that all dermatologists who work with PAs, the PAs themselves, and the billing staff need to fully understand Medicare “incident to” rules to […]
July 25, 2016